Andra AP fonden Invests $1.30 Million in Solventum Co. (NYSE:SOLV)

Andra AP fonden bought a new stake in Solventum Co. (NYSE:SOLV - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 19,715 shares of the company's stock, valued at approximately $1,302,000.

Other institutional investors have also modified their holdings of the company. Janney Montgomery Scott LLC increased its stake in shares of Solventum by 9.8% during the third quarter. Janney Montgomery Scott LLC now owns 42,931 shares of the company's stock worth $2,993,000 after acquiring an additional 3,848 shares during the period. Van ECK Associates Corp raised its stake in shares of Solventum by 53.9% during the 3rd quarter. Van ECK Associates Corp now owns 36,694 shares of the company's stock worth $2,660,000 after buying an additional 12,847 shares in the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in shares of Solventum by 29.0% in the third quarter. Robeco Institutional Asset Management B.V. now owns 27,826 shares of the company's stock valued at $1,940,000 after buying an additional 6,260 shares in the last quarter. Asset Management One Co. Ltd. grew its holdings in Solventum by 0.9% during the third quarter. Asset Management One Co. Ltd. now owns 53,597 shares of the company's stock worth $3,737,000 after acquiring an additional 464 shares during the period. Finally, Concurrent Investment Advisors LLC purchased a new position in Solventum in the third quarter worth $213,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on SOLV shares. Mizuho upped their price target on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research note on Monday, March 3rd. Bank of America increased their target price on shares of Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a report on Wednesday, February 26th. The Goldman Sachs Group upped their price target on Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a report on Monday, March 3rd. Piper Sandler lifted their price objective on Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a report on Friday, February 28th. Finally, Morgan Stanley boosted their target price on Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $79.86.

Remove Ads

Solventum Price Performance

Shares of NYSE:SOLV traded down $1.57 on Thursday, hitting $72.44. The company had a trading volume of 870,487 shares, compared to its average volume of 1,436,098. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The company has a market cap of $12.53 billion and a PE ratio of 26.34. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The business has a 50 day moving average of $74.24 and a 200 day moving average of $70.96.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.